



DOCKET NO.: L00461.70099.US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Van den Eynde and Boon-Falleur  
Serial No.: 09/674,593  
Confirmation No.: 9143  
Filing Date: June 7, 2001  
Title: TUMOR ASSOCIATED ANTIGEN ENCODED BY THE REVERSE STRAND OF A NEW UBIQUITOUSLY EXPRESSED GENE

Examiner: Misook Yu  
Art Unit: 1642

#  
14  
100  
11-15/02

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 5th day of November, 2002.

June Watson

Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE TO SECOND RESTRICTION REQUIREMENT**

In response to the second restriction requirement mailed October 11, 2002, Applicant hereby elects Group II (claims 1-2, 8-9, 12-13, 25, 66-67, and 71-78, as pertaining to SEQ ID NOs:1, 2 and 3) for prosecution, with traverse.

**REMARKS**

Applicants respectfully traverse the restriction of the RUR-1 sense and RUR-1 antisense sequences, as both groups relate to the same inventive concept of RUR-1 related molecules. The Examiner has asserted that SEQ ID NO:1 and SEQ ID NO:4 are "unrelated sequences." The Examiner appears to base the restriction between the sequences on a conventional definition of "sense" and "antisense" nucleotide sequences. Applicants agree that the claimed RUR-1 "sense" and "antisense" molecules may not fit the conventional definition of such sequences. (Applicants also note that the "antisense" sequences were alternatively termed "RUR-1 antiparallel" and "RUR-1 reverse strand", see first paragraph of Detailed Description). However, the sequences clearly are related, as they appear to be expressed from the same gene as initiated by two different

RECEIVED  
NOV 14 2002  
TECH CENTER 1600/2900